# data[].attributes.title
Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells

# data[].attributes.body.value
Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.
The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.

# data[].attributes.body.processed
Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.
The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov.

# data[].attributes.field_commercial_applications.value
Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants.

# data[].attributes.field_commercial_applications.processed
Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants.

# data[].attributes.field_competitive_advantages.value
Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos.

Detection of both mouse and human Eos, enabling application to human research.

Precise detection and measurement of Treg cells in diverse sample types.

# data[].attributes.field_competitive_advantages.processed
Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos.

Detection of both mouse and human Eos, enabling application to human research.

Precise detection and measurement of Treg cells in diverse sample types.

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.

# data[].attributes.field_publications[].value
Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838)

# data[].attributes.field_publications[].processed
Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838)

# data[].attributes.field_technology_names[]
Anti-mouse Ikzf4 (Eos) Monoclonal Antibody

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR

# data[].attributes.body.value
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.body.processed
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_commercial_applications.value
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_commercial_applications.processed
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_competitive_advantages.value
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_competitive_advantages.processed
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_licensingcontact_htmls[]
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].processed
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.title
Human antibodies with anti-lymphocyte specificities and lytic activity

# data[].attributes.body.value
Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.

By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.

# data[].attributes.body.processed
Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.

By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov.

# data[].attributes.field_commercial_applications.value
Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions

# data[].attributes.field_commercial_applications.processed
Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions

# data[].attributes.field_competitive_advantages.value
First fully human IgM antibody that binds to and kills B cells

Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response

B-cell death observed at concentrations as low as 0.01Nm

Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates

# data[].attributes.field_competitive_advantages.processed
First fully human IgM antibody that binds to and kills B cells

Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response

B-cell death observed at concentrations as low as 0.01Nm

Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE

# data[].attributes.field_technology_names[]
Human antibodies with anti-lymphocyte specificities and lytic activity linked to ICL.

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR

# data[].attributes.title
Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy

# data[].attributes.body.value
T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.

Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.

The Laboratory of Cellular and Molecular Biology, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.

Competitive Advantages:

Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via:

Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation

Directly triggering the downstream signaling cascade could cause more potent activation of T cells

LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion

Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable

Commercial Applications:

Treatment of hematological malignancies and solid tumors

Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy

# data[].attributes.body.processed
T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.

Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.

The Laboratory of Cellular and Molecular Biology, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.

Competitive Advantages:

Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via:

Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation

Directly triggering the downstream signaling cascade could cause more potent activation of T cells

LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion

Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable

Commercial Applications:

Treatment of hematological malignancies and solid tumors

Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy

# data[].attributes.field_licensingcontact_hrefs[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].value
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patents[].value
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patents[].processed
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
RECOMBINANT MOLECULES CONTAINING LINKER FOR ACTIVATION OF T CELLS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS  AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
Chimeric adaptor and kinase signaling proteins and their use in immunotherapy

# data[].attributes.field_publications[].value
Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps

# data[].attributes.field_publications[].processed
Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps

# data[].attributes.field_publications[].value
Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation

# data[].attributes.field_publications[].processed
Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation

# data[].attributes.field_publications[].value
Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)

# data[].attributes.field_publications[].processed
Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)

# data[].attributes.field_related_inventions[].processed
E-159-2009

# data[].attributes.field_technology_names[]
Recombinant Molecule Containing LAT For Use In T Cell Immunotherapy

# data[].attributes.field_technology_names[]
Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy

# data[].attributes.title
Levonorgestrel Butanoate Formulation and Methods Relating Thereto

# data[].attributes.body.value
Summary:

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.

Description of Technology:

This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese – increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.

Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.

Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.

NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.

Potential Commercial Applications:

Injectable contraceptive use by humans

Use in the treatment of progestin-related diseases

Competitive Advantages:

Safer for women with high-risk conditions

Self-subcutaneous and reversible injectable

Long-lasting contraceptive effects

Increased stability relative to previous formulations

Amenable to large-scale manufacture relative to previous formulations

Estrogen free contraceptive

Progestin only self-injectable contraceptive

# data[].attributes.body.processed
Summary:

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.

Description of Technology:

This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese – increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.

Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.

Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.

NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.

Potential Commercial Applications:

Injectable contraceptive use by humans

Use in the treatment of progestin-related diseases

Competitive Advantages:

Safer for women with high-risk conditions

Self-subcutaneous and reversible injectable

Long-lasting contraceptive effects

Increased stability relative to previous formulations

Amenable to large-scale manufacture relative to previous formulations

Estrogen free contraceptive

Progestin only self-injectable contraceptive

# data[].attributes.field_keywords[]
National Institute of Child Health and Human Development

# data[].attributes.field_licensingcontact_htmls[]
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_licensing_contacts[].value
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patents[].processed
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_technology_names[]
Levonorgestrel Prodrug Formulation And Methods Relating Thereto

# data[].attributes.title
Novel malaria vaccine candidates comprising engineered nanoparticles

# data[].attributes.body.value
Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
Malaria vaccinology

# data[].attributes.field_commercial_applications.processed
Malaria vaccinology

# data[].attributes.field_competitive_advantages.value
Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.

# data[].attributes.field_competitive_advantages.processed
Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patent_titles[]
MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF

# data[].attributes.field_patent_titles[]
MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF

# data[].attributes.field_publications[].value
Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)

# data[].attributes.field_publications[].processed
Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)

# data[].attributes.field_technology_names[]
Novel malaria vaccine candidates comprising engineered nanoparticles

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIH - NIAID

# data[].attributes.title
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

# data[].attributes.body.value
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.

The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:

The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.

The artificial immunogens retained structured transmission blocking epitopes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.

The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:

The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.

The artificial immunogens retained structured transmission blocking epitopes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023.

# data[].attributes.field_commercial_applications.value
This technology could be used alone or in combination with existing malaria vaccines.

# data[].attributes.field_commercial_applications.processed
This technology could be used alone or in combination with existing malaria vaccines.

# data[].attributes.field_competitive_advantages.value
The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.

Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.

# data[].attributes.field_competitive_advantages.processed
The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.

Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patents[].value
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patent_htmls[]
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_technology_names[]
A Novel Strategy To Produce 6-cys Proteins Based On Pfs230D1 Domain Fusions

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.title
Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization

# data[].attributes.body.value
This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology’s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.

# data[].attributes.body.processed
This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology’s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.

# data[].attributes.field_commercial_applications.processed
Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.

# data[].attributes.field_competitive_advantages.value
No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates

# data[].attributes.field_competitive_advantages.processed
No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patent_titles[]
NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS

# data[].attributes.field_patent_titles[]
NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS

# data[].attributes.field_publications[].value
Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023

# data[].attributes.field_publications[].processed
Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023

# data[].attributes.field_technology_names[]
Novel malaria vaccine candidates comprising a stabilized designs of AMA1 and RON2 antigens

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.title
Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies

# data[].attributes.body.value
This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite's immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.

# data[].attributes.body.processed
This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite's immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.

# data[].attributes.field_commercial_applications.processed
This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.

# data[].attributes.field_competitive_advantages.value
This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.

# data[].attributes.field_competitive_advantages.processed
This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patent_titles[]
METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE

# data[].attributes.field_patent_titles[]
METHOD OF IMMMUNOFOCUSING AN IMMUNE RESPONSE

# data[].attributes.field_publications[].value
Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3

# data[].attributes.field_publications[].processed
Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized MSP1 Malaria Antigens And High Affinity Anti-MSP1 Human Monoclonal Antibodies And Their Use

# data[].attributes.title
Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology

# data[].attributes.body.value
The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.

# data[].attributes.body.processed
The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.

# data[].attributes.field_commercial_applications.processed
This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.

# data[].attributes.field_competitive_advantages.value
The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.

# data[].attributes.field_competitive_advantages.processed
The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patents[].processed
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patent_titles[]
Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use

# data[].attributes.title
Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use

# data[].attributes.body.value
Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; peter.tung@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; peter.tung@nih.gov.

# data[].attributes.field_commercial_applications.value
Novel SARS-CoV-2 vaccine.

Improved SARS-CoV-2 diagnostics using stabilized antigens.

Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).

# data[].attributes.field_commercial_applications.processed
Novel SARS-CoV-2 vaccine.

Improved SARS-CoV-2 diagnostics using stabilized antigens.

Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).

# data[].attributes.field_competitive_advantages.value
Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.

Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.

Computational method of designing vaccine antigens.

# data[].attributes.field_competitive_advantages.processed
Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.

Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.

Computational method of designing vaccine antigens.

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patent_titles[]
COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE

# data[].attributes.field_patent_titles[]
Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use

# data[].attributes.field_publications[].value
Dickey TH, et al.

# data[].attributes.field_publications[].processed
Dickey TH, et al.

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use

# data[].attributes.title
Novel VAR2CSA Immunogens and Methods of Use Thereof

# data[].attributes.body.value
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease.

# data[].attributes.body.processed
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; Peter Tung@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; Peter Tung@nih.gov.

# data[].attributes.field_commercial_applications.value
The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents.

Placental malaria vaccine

CSA-binding proteins for cancer therapeutics

# data[].attributes.field_commercial_applications.processed
The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents.

Placental malaria vaccine

CSA-binding proteins for cancer therapeutics

# data[].attributes.field_competitive_advantages.value
Strain-transcending immunogens for vaccination

Improved immunogen production through expression of key protein regions

# data[].attributes.field_competitive_advantages.processed
Strain-transcending immunogens for vaccination

Improved immunogen production through expression of key protein regions

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patent_titles[]
NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF

# data[].attributes.field_patent_titles[]
NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF

# data[].attributes.field_technology_names[]
New Composition Of Matter Comprising Immunogens That Will Protect Against Placental Malaria, And Proteins That Can Be Used For Cancer Diagnostics And Therapeutics

# data[].attributes.title
Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

# data[].attributes.body.value
Summary:

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

Description of Technology:

ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.

This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation–serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.

The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.

Potential Commercial Applications:

Solid tumors expressing p53 or KRAS mutations

Hematologic malignancies

Melanoma

Competitive Advantages:

Versatile platform for inducible cytokine regulation

Superior survival in mouse models compared with TCR-only T-cells

Enhanced tumor cell killing and long-term survival in murine models

Decreased IL-12–associated toxicity

Maintenance of higher IL-12 expression

Improved sensitivity to lenalidomide-mediated degradation

# data[].attributes.body.processed
Summary:

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

Description of Technology:

ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.

This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation–serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.

The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.

Potential Commercial Applications:

Solid tumors expressing p53 or KRAS mutations

Hematologic malignancies

Melanoma

Competitive Advantages:

Versatile platform for inducible cytokine regulation

Superior survival in mouse models compared with TCR-only T-cells

Enhanced tumor cell killing and long-term survival in murine models

Decreased IL-12–associated toxicity

Maintenance of higher IL-12 expression

Improved sensitivity to lenalidomide-mediated degradation

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs).

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs).

# data[].attributes.field_licensingcontact_hrefs[]
burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts[].value
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_publications[].value
Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344

# data[].attributes.field_publications[].processed
Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344

# data[].attributes.field_technology_names[]
Drug-regulatable, inducible expression of membrane-bound interleukin 12 for use in adoptive cell therapy.

# data[].attributes.field_technology_owners[]
National Cancer Institute (NCI), Surgery Branch

# data[].attributes.title
Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces

# data[].attributes.body.value
Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less).

Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin.
This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead.

# data[].attributes.body.processed
Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less).

Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin.

This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day

Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms

Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint

Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk

Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))

May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof

# data[].attributes.field_commercial_applications.processed
Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day

Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms

Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint

Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk

Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))

May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof

# data[].attributes.field_competitive_advantages.value
Safe for use on skin

Quick and easy to use

Portable and convenient to use wherever lead is present

Effectively removes Pb ions from the skin to less than the limit of identification

Can be used to complement other lead detection methods

Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above

# data[].attributes.field_competitive_advantages.processed
Safe for use on skin

Quick and easy to use

Portable and convenient to use wherever lead is present

Effectively removes Pb ions from the skin to less than the limit of identification

Can be used to complement other lead detection methods

Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.

# data[].attributes.field_patents[].value
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patent_titles[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_patent_titles[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_publications[].value
Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)

# data[].attributes.field_publications[].processed
Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)

# data[].attributes.field_publications[].value
Esswein EJ, et al.

# data[].attributes.field_publications[].processed
Esswein EJ, et al.

# data[].attributes.field_publications[].value
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way

# data[].attributes.field_publications[].processed
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way

# data[].attributes.field_publications[].value
NIOSH. (2018). Workplace Safety and Health Topics

# data[].attributes.field_publications[].processed
NIOSH. (2018). Workplace Safety and Health Topics

# data[].attributes.field_related_inventions[].processed
E-336-2013-0

# data[].attributes.field_technology_names[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Handwipe Disclosing Method for Detecting the Presence of Lead

# data[].attributes.body.value
Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination.

US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used).

This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead.

# data[].attributes.body.processed
Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination.

US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used).

This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead

Informing employers and workers on potential lead contamination and exposure

Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods

Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools
Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel

Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))

# data[].attributes.field_commercial_applications.processed
Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead

Informing employers and workers on potential lead contamination and exposure

Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods

Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools

Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel

Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))

# data[].attributes.field_competitive_advantages.value
Safe for use on skin

Quick and easy to use
-
Portable and can be used during field evaluations

Can be used wherever lead is present

Simple color change readout indicates the presence of lead on a surface

Lead concentration can be inferred by degree of color shift

Can be used to guide and evaluate lead removal methods

# data[].attributes.field_competitive_advantages.processed
Safe for use on skin

Quick and easy to use
-
Portable and can be used during field evaluations

Can be used wherever lead is present

Simple color change readout indicates the presence of lead on a surface

Lead concentration can be inferred by degree of color shift

Can be used to guide and evaluate lead removal methods

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patents[].value
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_publications[].value
Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.

# data[].attributes.field_publications[].processed
Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.

# data[].attributes.field_publications[].value
Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).

# data[].attributes.field_publications[].processed
Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).

# data[].attributes.field_publications[].value
Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).

# data[].attributes.field_publications[].processed
Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).

# data[].attributes.field_publications[].value
Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).

# data[].attributes.field_publications[].processed
Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).

# data[].attributes.field_publications[].value
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!

# data[].attributes.field_publications[].processed
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!

# data[].attributes.field_publications[].value
NIOSH. (2018). Workplace Safety and Health Topics: Lead.

# data[].attributes.field_publications[].processed
NIOSH. (2018). Workplace Safety and Health Topics: Lead.

# data[].attributes.field_publications[].value
NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.

# data[].attributes.field_publications[].processed
NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.

# data[].attributes.field_related_inventions[].processed
E-221-2013-0

# data[].attributes.field_technology_names[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring

# data[].attributes.body.value
Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred.

CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications.

# data[].attributes.body.processed
Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred.

CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.  For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.  For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330.

# data[].attributes.field_commercial_applications.value
Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures

Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

Occupational safety and health

Monitoring/public health surveillance

# data[].attributes.field_commercial_applications.processed
Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures

Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

Occupational safety and health

Monitoring/public health surveillance

# data[].attributes.field_competitive_advantages.value
Near real-time and continuous automatic measurement of aerosol and bioaerosol

Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity

High sample throughput collection

- Allows space-saving and miniature designs for easy integration into portable instruments

Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results

# data[].attributes.field_competitive_advantages.processed
Near real-time and continuous automatic measurement of aerosol and bioaerosol

Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity

High sample throughput collection

- Allows space-saving and miniature designs for easy integration into portable instruments

Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.

# data[].attributes.field_patents[].value
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patent_titles[]
METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES

# data[].attributes.field_patent_titles[]
METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES

# data[].attributes.field_related_inventions[].processed
E-291-2016-0

# data[].attributes.field_related_inventions[].processed
E-205-2013-0

# data[].attributes.field_related_inventions[].processed
E-163-2013-0

# data[].attributes.field_related_inventions[].processed
E-026-2014-0

# data[].attributes.field_related_inventions[].processed
E-146-2013-0

# data[].attributes.field_technology_names[]
Methods For High Sample Throughput Collection And Trace Chemical Analysis Of Aerosols Using Laser And Optical Spectroscopies

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs

# data[].attributes.body.value
Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology.

# data[].attributes.body.processed
Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology.

# data[].attributes.field_collaboration_description.value
The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at keg2@cdc.gov or 1-513-533-8686.

# data[].attributes.field_collaboration_description.processed
The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at keg2@cdc.gov or 1-513-533-8686.

# data[].attributes.field_commercial_applications.value
Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies

Kits can be used to assess decontamination procedures

Kits can be used to assess protective equipment and closed system drug-transfer devices

Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces

# data[].attributes.field_commercial_applications.processed
Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies

Kits can be used to assess decontamination procedures

Kits can be used to assess protective equipment and closed system drug-transfer devices

Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces

# data[].attributes.field_competitive_advantages.value
Near real-time results

Can be used in various locations, on surfaces, and on protective equipment

Simple to use

Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers

# data[].attributes.field_competitive_advantages.processed
Near real-time results

Can be used in various locations, on surfaces, and on protective equipment

Simple to use

Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patents[].value
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_technology_names[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring

# data[].attributes.body.value
Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement.

# data[].attributes.body.processed
Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.

# data[].attributes.field_commercial_applications.value
Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

# data[].attributes.field_commercial_applications.processed
Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

# data[].attributes.field_competitive_advantages.value
Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings

Enables elemental analysis of aerosols in near real-time

Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources

# data[].attributes.field_competitive_advantages.processed
Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings

Enables elemental analysis of aerosols in near real-time

Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patents[].value
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patents[].processed
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patent_titles[]
Elemental Analysis of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY

# data[].attributes.field_publications[].value
Zheng L, et al.

# data[].attributes.field_publications[].processed
Zheng L, et al.

# data[].attributes.field_related_inventions[].processed
E-205-2013-0

# data[].attributes.field_related_inventions[].processed
E-163-2013-0

# data[].attributes.field_technology_names[]
Elemental Analysis Of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters

# data[].attributes.body.value
A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.

The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm.

# data[].attributes.body.processed
A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.

The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters

Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions

Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.

# data[].attributes.field_commercial_applications.processed
Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters

Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions

Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.

# data[].attributes.field_competitive_advantages.value
Technology senses and removes particles

Ability to monitor several ligands (molecules that bind with others) at once

An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters

To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions

Not based on electrochemical technology

Apparatus is added to gas canisters

Light weight and inexpensive

Uses a light source and mini spectrometer

Uses color and/or audible detection

# data[].attributes.field_competitive_advantages.processed
Technology senses and removes particles

Ability to monitor several ligands (molecules that bind with others) at once

An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters

To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions

Not based on electrochemical technology

Apparatus is added to gas canisters

Light weight and inexpensive

Uses a light source and mini spectrometer

Uses color and/or audible detection

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patents[].value
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patent_titles[]
Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters

# data[].attributes.field_patent_titles[]
Cobinamide-Based Materials For Optical Sensing And Gas Removal

# data[].attributes.field_publications[].value
Greenawald LA, et al.

# data[].attributes.field_publications[].processed
Greenawald LA, et al.

# data[].attributes.field_technology_names[]
Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), University of California, San Diego

# data[].attributes.title
Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls

# data[].attributes.body.value
Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work.

CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability.

# data[].attributes.body.processed
Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work.

CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability.

# data[].attributes.field_collaboration_description.value
The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
May be used widely throughout the residential and commercial construction building industry

May be used to safeguard roof workers

May be useful to do-it-yourself (DIY) home improvers

# data[].attributes.field_commercial_applications.processed
May be used widely throughout the residential and commercial construction building industry

May be used to safeguard roof workers

May be useful to do-it-yourself (DIY) home improvers

# data[].attributes.field_competitive_advantages.value
A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction

Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through

Roof bracket can provide worker support when moving up-slope while installing roofing shingles

Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off

# data[].attributes.field_competitive_advantages.processed
A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction

Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through

Roof bracket can provide worker support when moving up-slope while installing roofing shingles

Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.

# data[].attributes.field_patents[].value
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patent_titles[]
BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN

# data[].attributes.field_publications[].value
Bobick-TG, et al.

# data[].attributes.field_publications[].processed
Bobick-TG, et al.

# data[].attributes.field_publications[].value
Bobick T, et al.

# data[].attributes.field_publications[].processed
Bobick T, et al.

# data[].attributes.field_publications[].value
Bobick-TG, et al.

# data[].attributes.field_publications[].processed
Bobick-TG, et al.

# data[].attributes.field_publications[].value
Bobick-TG, el al.

# data[].attributes.field_publications[].processed
Bobick-TG, el al.

# data[].attributes.field_related_inventions[].processed
E-141-2013-0

# data[].attributes.field_technology_names[]
BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise

# data[].attributes.body.value
This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.

The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss.

# data[].attributes.body.processed
This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.

The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss.

# data[].attributes.field_commercial_applications.value
Assessment of potentially hazardous levels of impulse noise

Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades

Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss

# data[].attributes.field_commercial_applications.processed
Assessment of potentially hazardous levels of impulse noise

Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades

Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss

# data[].attributes.field_competitive_advantages.value
This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.

# data[].attributes.field_competitive_advantages.processed
This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_publications[].value
Kardous CA, et al.

# data[].attributes.field_publications[].processed
Kardous CA, et al.

# data[].attributes.field_publications[].value
Kardous CA, et al.

# data[].attributes.field_publications[].processed
Kardous CA, et al.

# data[].attributes.field_publications[].value
Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.

# data[].attributes.field_publications[].processed
Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.

# data[].attributes.field_publications[].value
Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.

# data[].attributes.field_publications[].processed
Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.

# data[].attributes.field_technology_names[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury

# data[].attributes.body.value
CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury.  PEAS is a noninvasive, real-time, instrument-based system.  Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis.  During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time.  The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message.  Additionally, the smart phone stores the sent text message for archiving and further data analysis.

# data[].attributes.body.processed
CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury.  PEAS is a noninvasive, real-time, instrument-based system.  Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis.  During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time.  The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message.  Additionally, the smart phone stores the sent text message for archiving and further data analysis.

# data[].attributes.field_commercial_applications.value
Safety officers within the environmental, safety, and health departments of public and private entities

Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking

Workers' well-being concern groups

Insurers and workers' compensation operations

Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting

# data[].attributes.field_commercial_applications.processed
Safety officers within the environmental, safety, and health departments of public and private entities

Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking

Workers' well-being concern groups

Insurers and workers' compensation operations

Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting

# data[].attributes.field_competitive_advantages.value
No comparable technology currently exists in the marketplace

Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm

Portable; approximately the size of a mobile phone and uses comparable technology

# data[].attributes.field_competitive_advantages.processed
No comparable technology currently exists in the marketplace

Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm

Portable; approximately the size of a mobile phone and uses comparable technology

# data[].attributes.field_development_status.value
Early-stage

In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
Early-stage

In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patent_titles[]
Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries

# data[].attributes.field_patent_titles[]
SYSTEM AND METHOD TO PREDICT AND AVOID MUSCULOSKELETAL INJURIES

# data[].attributes.field_technology_names[]
Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications

# data[].attributes.body.value
This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.

This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity.

# data[].attributes.body.processed
This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.

This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity.

# data[].attributes.field_commercial_applications.value
Knee pain, low-back pain alleviation and prevention

Improved workplace ergonomics

Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce

Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting

# data[].attributes.field_commercial_applications.processed
Knee pain, low-back pain alleviation and prevention

Improved workplace ergonomics

Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce

Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting

# data[].attributes.field_competitive_advantages.value
Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity

Device is extremely portable

Easily attaches to a user's lower leg; allows for unhindered movement and ambulation

Device automatically moves with the user; no manual readjustments or manipulations are required

Durable and nonflammable

Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces

# data[].attributes.field_competitive_advantages.processed
Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity

Device is extremely portable

Easily attaches to a user's lower leg; allows for unhindered movement and ambulation

Device automatically moves with the user; no manual readjustments or manipulations are required

Durable and nonflammable

Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Mobile Instrumentation for the Detection and Sampling of Aerosol Particles

# data[].attributes.body.value
Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.

CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter < 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation.

# data[].attributes.body.processed
Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.

CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation.

# data[].attributes.field_commercial_applications.value
Condensation particle detectors

Particle size magnification systems

Microfluidic devices for sampling, detection, and growth of hazardous particles

# data[].attributes.field_commercial_applications.processed
Condensation particle detectors

Particle size magnification systems

Microfluidic devices for sampling, detection, and growth of hazardous particles

# data[].attributes.field_competitive_advantages.value
Cost-effective

Offers overall reduction of measurement time

Requires minimal power to operate

Mobile, wearable

Space-saving miniature systems as small as 1" x 1" x 3"

# data[].attributes.field_competitive_advantages.processed
Cost-effective

Offers overall reduction of measurement time

Requires minimal power to operate

Mobile, wearable

Space-saving miniature systems as small as 1" x 1" x 3"

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.

# data[].attributes.field_patents[].value
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patent_titles[]
Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes

# data[].attributes.field_patent_titles[]
Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes

# data[].attributes.field_patent_titles[]
AEROSOL PARTICLE GROWTH SYSTEMS FOR PERSONAL SAMPLING APPLICATIONS USING POLYMER ELECTROLYTE MEMBRANES

# data[].attributes.field_related_inventions[].processed
E-146-2013-0

# data[].attributes.field_technology_names[]
Aerosol Particle Growth Systems For Personal Sampling Applications Using Proton Exchange Membranes

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), Regents of the University of Minnesota

# data[].attributes.body.value
Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.

Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts.

# data[].attributes.body.processed
Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.

Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts.

# data[].attributes.field_commercial_applications.value
Battery charger that can be used on personal or commercial boats.

Maritime battery charger that can be used for specialized rescue vessels.

# data[].attributes.field_commercial_applications.processed
Battery charger that can be used on personal or commercial boats.

Maritime battery charger that can be used for specialized rescue vessels.

# data[].attributes.field_competitive_advantages.value
Charging system is configured to be powered by wave action.

Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.

Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.

# data[].attributes.field_competitive_advantages.processed
Charging system is configured to be powered by wave action.

Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.

Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.

# data[].attributes.field_development_status.value
Early-stage

Prototype

# data[].attributes.field_development_status.processed
Early-stage

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.body.value
Shrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools.

Researchers at NIOSH have developed guarding devices to protect shrimp boat winch operators from being entangled in the continuously spinning cathead spools. The mechanical guards feature a swinging functionality covering the catheads after the main trawl operations, allowing access to the normal operation of the catheads.

# data[].attributes.body.processed
Shrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools.

Researchers at NIOSH have developed guarding devices to protect shrimp boat winch operators from being entangled in the continuously spinning cathead spools. The mechanical guards feature a swinging functionality covering the catheads after the main trawl operations, allowing access to the normal operation of the catheads.

# data[].attributes.field_commercial_applications.value
Protective guards used to protect shrimp boat operators from being entangled in cathead spools.

Cathead guards used to protect operators in the mining, oil, and gas industries where cathead winch spools are used.

Guards can be used in boating industry to protect operators of anchor windlasses.

# data[].attributes.field_commercial_applications.processed
Protective guards used to protect shrimp boat operators from being entangled in cathead spools.

Cathead guards used to protect operators in the mining, oil, and gas industries where cathead winch spools are used.

Guards can be used in boating industry to protect operators of anchor windlasses.

# data[].attributes.field_competitive_advantages.value
Swing-away mechanism of cathead guard protects operators from becoming entangled in spinning cathead spools.

Designed specifically to address safety issues with industry winch protocols.

# data[].attributes.field_competitive_advantages.processed
Swing-away mechanism of cathead guard protects operators from becoming entangled in spinning cathead spools.

Designed specifically to address safety issues with industry winch protocols.

# data[].attributes.field_development_status.value
Early-stage

Prototype

# data[].attributes.field_development_status.processed
Early-stage
Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard.

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy

# data[].attributes.body.value
This CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS).

Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine and ultrafine aerosols using these techniques is particularly challenging due to small plasma volume, miniscule sample mass, and inferior sampling statistics, often leading to poor detection limits and precision.

This technology utilizes a microwave plasma-based detection system for aerosol analysis that features increased microplasma lifetime, repeatability, and stability over currently-available pulsed microplasma-based methods. This system produces microplasma lifetimes in the range of 5 to 50 milliseconds, a duration that is orders of magnitude larger than lifetimes for laser-induced or spark plasmas, as well as larger plasma volumes, which together are expected to provide improved detection limits over currently-available techniques.

# data[].attributes.body.processed
This CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS).

Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine and ultrafine aerosols using these techniques is particularly challenging due to small plasma volume, miniscule sample mass, and inferior sampling statistics, often leading to poor detection limits and precision.

This technology utilizes a microwave plasma-based detection system for aerosol analysis that features increased microplasma lifetime, repeatability, and stability over currently-available pulsed microplasma-based methods. This system produces microplasma lifetimes in the range of 5 to 50 milliseconds, a duration that is orders of magnitude larger than lifetimes for laser-induced or spark plasmas, as well as larger plasma volumes, which together are expected to provide improved detection limits over currently-available techniques.

# data[].attributes.field_commercial_applications.value
Elemental quantification of aerosols in near real-time

Air pollution studies, Particulate Matter monitoring

Hazardous materials exposure determinations and identification

Biodefense, chemical-defense, homeland-security applications

Environmental and occupational epidemiology

Evaluation of engineering controls

# data[].attributes.field_commercial_applications.processed
Elemental quantification of aerosols in near real-time

Air pollution studies, Particulate Matter monitoring

Hazardous materials exposure determinations and identification

Biodefense, chemical-defense, homeland-security applications

Environmental and occupational epidemiology

Evaluation of engineering controls

# data[].attributes.field_competitive_advantages.value
Makes it possible to conduct accurate, near-real-time measurement of the elemental composition of aerosols in industrial and ambient atmospheres

Corona field stabilizes the microwave plasma and results in repeatable plasma formation

Larger size of CAMPS plasma provides sufficient plasma volume which can lead to complete ablation of deposited aerosol in the tip of the electrode

Longer duration of CAMPS plasma (~10-50 ms) allows longer integration time which results in signal enhancement

# data[].attributes.field_competitive_advantages.processed
Makes it possible to conduct accurate, near-real-time measurement of the elemental composition of aerosols in industrial and ambient atmospheres

Corona field stabilizes the microwave plasma and results in repeatable plasma formation

Larger size of CAMPS plasma provides sufficient plasma volume which can lead to complete ablation of deposited aerosol in the tip of the electrode

Longer duration of CAMPS plasma (~10-50 ms) allows longer integration time which results in signal enhancement

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/652,593
Filed on 2012-05-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/652,593
Filed on 2012-05-02
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 9,091,597
Filed on 2013-03-14
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 9,091,597
Filed on 2013-03-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/652,593
Filed on 2012-05-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 9,091,597
Filed on 2013-03-14
Status: Issued

# data[].attributes.field_related_inventions[].processed
E-205-2013-0

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), Envimetrics, LLC

# data[].attributes.title
Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis

# data[].attributes.body.value
This CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition.

Workers in many outdoor occupations move about frequently during a typical day of work. Certain workers, such as agricultural and construction workers, are particularly mobile. This exposure monitoring system combines geographical location with real-time sensors and outputs the information to a user-friendly interface. By linking worker location throughout the workday to exposure levels from real-time monitors, Local Positioning System (LPS) units (with integrated software processing of data) identify and document where to direct hazard exposure analysis and control efforts. Post-processing of LPS data enables researchers, regulatory inspectors, and industry safety and health personnel to map exposure intensity and location, reveal hot spots to identify sources, and provide exposure intensity distributions to increase workplace safety.

# data[].attributes.body.processed
This CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition.

Workers in many outdoor occupations move about frequently during a typical day of work. Certain workers, such as agricultural and construction workers, are particularly mobile. This exposure monitoring system combines geographical location with real-time sensors and outputs the information to a user-friendly interface. By linking worker location throughout the workday to exposure levels from real-time monitors, Local Positioning System (LPS) units (with integrated software processing of data) identify and document where to direct hazard exposure analysis and control efforts. Post-processing of LPS data enables researchers, regulatory inspectors, and industry safety and health personnel to map exposure intensity and location, reveal hot spots to identify sources, and provide exposure intensity distributions to increase workplace safety.

# data[].attributes.field_commercial_applications.value
Collection, analysis and display of mutual, real-time conditional and 3-dimensional position data

Outdoor occupational exposure assessment with various real-time sensors/monitors (e.g., HAZMAT crews, safety inspection, etc.)

Solid state "bread crumbs" allowing a person or machine to retrace their path

Tracking of objects, animals or people, including sensing of their internal condition or environmental conditions

Environmental pollution source-point monitoring and investigation

# data[].attributes.field_commercial_applications.processed
Collection, analysis and display of mutual, real-time conditional and 3-dimensional position data

Outdoor occupational exposure assessment with various real-time sensors/monitors (e.g., HAZMAT crews, safety inspection, etc.)

Solid state "bread crumbs" allowing a person or machine to retrace their path

Tracking of objects, animals or people, including sensing of their internal condition or environmental conditions

Environmental pollution source-point monitoring and investigation

# data[].attributes.field_competitive_advantages.value
Correlates real-time position and real-time condition data for multiple commercial/industrial applications

An add-on capability for any sensor(s) when measurement of a location is also useful

System is highly customizable and can be easily adapted for additional monitoring of noise, dust, gases, and vapor, heat stress, etc. exposures

Automated system provides greater efficiency and greater feedback than video monitoring systems

An integrated alarm will alert users to potential hazards

# data[].attributes.field_competitive_advantages.processed
Correlates real-time position and real-time condition data for multiple commercial/industrial applications

An add-on capability for any sensor(s) when measurement of a location is also useful

System is highly customizable and can be easily adapted for additional monitoring of noise, dust, gases, and vapor, heat stress, etc. exposures

Automated system provides greater efficiency and greater feedback than video monitoring systems

An integrated alarm will alert users to potential hazards

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis.

# data[].attributes.field_patents[].value
US Patent 7,191,097
Filed on 2004-03-31
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,191,097
Filed on 2004-03-31
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,191,097
Filed on 2004-03-31
Status: Abandoned

# data[].attributes.field_patent_titles[]
Method, Apparatus, And System For Assessing Conditions

# data[].attributes.field_publications[].value
Lee LA, et al.

# data[].attributes.field_publications[].processed
Lee LA, et al.

# data[].attributes.field_technology_names[]
Method, Apparatus, And System For Assessing Conditions

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques

# data[].attributes.body.value
This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation.

The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a laser-induced plasma) and the optical spectrometer to obtain elemental composition of aerosol particles. The unique features of this invention allow: i) semi-continuous or near-real-time measurement of elemental composition of aerosol particles, ii) measurement with high accuracy, precision, and repeatability, iii) collection of particles using electrostatic principles, iv) higher flow rates with smaller pumps because of a very low pressure drop, v) reliable calibration of the system, vi) easy miniaturization for portable instruments, and vii) lower detection limits, as needed, by increasing the particle collection time and/or sampling flow rate.

# data[].attributes.body.processed
This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation.

The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a laser-induced plasma) and the optical spectrometer to obtain elemental composition of aerosol particles. The unique features of this invention allow: i) semi-continuous or near-real-time measurement of elemental composition of aerosol particles, ii) measurement with high accuracy, precision, and repeatability, iii) collection of particles using electrostatic principles, iv) higher flow rates with smaller pumps because of a very low pressure drop, v) reliable calibration of the system, vi) easy miniaturization for portable instruments, and vii) lower detection limits, as needed, by increasing the particle collection time and/or sampling flow rate.

# data[].attributes.field_commercial_applications.value
Personal exposure measurements of metals

Air pollution studies

Elemental quantification in near real-time

Hazardous materials exposure determinations and identification

Biodefense, chemical-defense applications

Environmental and occupational epidemiology

Evaluation of engineering controls

# data[].attributes.field_commercial_applications.processed
Personal exposure measurements of metals

Air pollution studies

Elemental quantification in near real-time

Hazardous materials exposure determinations and identification

Biodefense, chemical-defense applications

Environmental and occupational epidemiology

Evaluation of engineering controls

# data[].attributes.field_competitive_advantages.value
This APU allows accurate, near-real-time measurement of the elemental composition of aerosol particles in industrial and ambient atmospheres

Can be readily miniaturized and integrated into existing portable plasma, Raman, or IR spectroscopy instruments to allow on-site, semi-continuous measurement of aerosol particles

Provides lower detection limits compared to earlier technology, as needed, by increasing the particle collection time and/or sampling flow rate

# data[].attributes.field_competitive_advantages.processed
This APU allows accurate, near-real-time measurement of the elemental composition of aerosol particles in industrial and ambient atmospheres

Can be readily miniaturized and integrated into existing portable plasma, Raman, or IR spectroscopy instruments to allow on-site, semi-continuous measurement of aerosol particles

Provides lower detection limits compared to earlier technology, as needed, by increasing the particle collection time and/or sampling flow rate

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques.

# data[].attributes.field_patents[].value
US Patent 8,970,840
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,970,840
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 8,970,840
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patent_titles[]
Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy

# data[].attributes.field_related_inventions[].processed
E-163-2013-0

# data[].attributes.field_technology_names[]
Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), TKC Global

# data[].attributes.title
Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function

# data[].attributes.body.value
CDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern.

Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respiration are observed, which are then related to tidal volume. Although the effects of gas compression on the WBP signal of normal mice may be negligible, gas compression in mice with altered breathing pattern and/or increased airway resistance can produce significant errors in the measurement of tidal volume. A major advantage of this novel AWBP technology is the ability to measure the tidal volume signal independent of gas compression. This is particularly useful when measuring mice that have been exposed to a respiratory irritant or toxin that increases airway resistance or the frequency content of the breathing pattern. Further, with slight hardware and software modifications the system may also be used to measure specific airway resistances.

# data[].attributes.body.processed
CDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern.

Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respiration are observed, which are then related to tidal volume. Although the effects of gas compression on the WBP signal of normal mice may be negligible, gas compression in mice with altered breathing pattern and/or increased airway resistance can produce significant errors in the measurement of tidal volume. A major advantage of this novel AWBP technology is the ability to measure the tidal volume signal independent of gas compression. This is particularly useful when measuring mice that have been exposed to a respiratory irritant or toxin that increases airway resistance or the frequency content of the breathing pattern. Further, with slight hardware and software modifications the system may also be used to measure specific airway resistances.

# data[].attributes.field_commercial_applications.value
Measurement of tidal volume, respiratory rate, and other breath rate parameters of laboratory animals

Research and animal modeling tool for in vivo pulmonary investigations of therapeutics efficacy and studying certain infectious diseases

Particularly useful when measuring animals exposed to a respiratory irritant or toxin that increases either airway resistance or the frequency

Noninvasive measurement of specific airway resistance and restrictions in an unrestrained animal

# data[].attributes.field_commercial_applications.processed
Measurement of tidal volume, respiratory rate, and other breath rate parameters of laboratory animals

Research and animal modeling tool for in vivo pulmonary investigations of therapeutics efficacy and studying certain infectious diseases

Particularly useful when measuring animals exposed to a respiratory irritant or toxin that increases either airway resistance or the frequency

Noninvasive measurement of specific airway resistance and restrictions in an unrestrained animal

# data[].attributes.field_competitive_advantages.value
System allows fast, efficient, noninvasive measurement of lab animal pulmonary function for numerous inhalation, toxicology research studies

Measures tidal volume signal independent of gas compression, increasing accuracy when gathering data from animals with altered breathing patterns and/or elevated airway resistance

System operates at a fixed frequency, and automatically tracks the change in sound amplitude as a function of time due to change in lung volume

# data[].attributes.field_competitive_advantages.processed
System allows fast, efficient, noninvasive measurement of lab animal pulmonary function for numerous inhalation, toxicology research studies

Measures tidal volume signal independent of gas compression, increasing accuracy when gathering data from animals with altered breathing patterns and/or elevated airway resistance

System operates at a fixed frequency, and automatically tracks the change in sound amplitude as a function of time due to change in lung volume

# data[].attributes.field_development_status.value
In vivo data available (animal)

In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In vivo data available (animal)

In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/958,537
Filed on 2007-07-06
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/958,537
Filed on 2007-07-06
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,328,729
Filed on 2009-01-08
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,328,729
Filed on 2009-01-08
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/958,537
Filed on 2007-07-06
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,328,729
Filed on 2009-01-08
Status: Abandoned

# data[].attributes.field_patent_titles[]
Acoustic Plethysmograph For Measuring Pulmonary Function

# data[].attributes.field_patent_titles[]
Acoustic Plethysmograph For Measuring Pulmonary Function

# data[].attributes.field_publications[].value
Reynolds JS, et al.

# data[].attributes.field_publications[].processed
Reynolds JS, et al.

# data[].attributes.field_publications[].value
Reynolds JS, et al.

# data[].attributes.field_publications[].processed
Reynolds JS, et al.

# data[].attributes.field_publications[].value
Daubenspeck JA , et al.

# data[].attributes.field_publications[].processed
Daubenspeck JA , et al.

# data[].attributes.field_technology_names[]
Acoustic Plethysmograph For Measuring Pulmonary Function

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Cable-line Safety System:  Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan

# data[].attributes.body.value
This CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency.  Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum.  As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch.  A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters.

# data[].attributes.body.processed
This CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency.  Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum.  As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch.  A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters.

# data[].attributes.field_commercial_applications.value
Retrofitting existing winches for additional safety and adherence to possible future regulations

Specifically designed and tested for the marine/fishing industries

Applications in mining, construction, forestry, and/or off-road automotive industries

Workers' well-being concern groups

Insurers of fishing vessels; also mining, construction and forestry operations

Manufacturers of cable reel trailers and wire-drawing machinery

# data[].attributes.field_commercial_applications.processed
Retrofitting existing winches for additional safety and adherence to possible future regulations

Specifically designed and tested for the marine/fishing industries

Applications in mining, construction, forestry, and/or off-road automotive industries

Workers' well-being concern groups

Insurers of fishing vessels; also mining, construction and forestry operations

Manufacturers of cable reel trailers and wire-drawing machinery

# data[].attributes.field_competitive_advantages.value
Complies with numerous international safety regulations requiring winches, drums and capstans to have a master on/off switch in easy reach for worker safety

Can be packaged as a ‘retrofit kit’ for integration with current commercial winch/drum usage

# data[].attributes.field_competitive_advantages.processed
Complies with numerous international safety regulations requiring winches, drums and capstans to have a master on/off switch in easy reach for worker safety

Can be packaged as a ‘retrofit kit’ for integration with current commercial winch/drum usage

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System:  Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System:  Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System:  Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System:  Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan.

# data[].attributes.field_related_inventions[].processed
E-504-2013-0

# data[].attributes.field_related_inventions[].processed
E-567-2013-0

# data[].attributes.field_related_inventions[].processed
E-568-2013-0

# data[].attributes.field_related_inventions[].processed
E-643-2013-0

# data[].attributes.field_technology_names[]
ELECTRO/HYDRAULIC EMERGENCY STOP DEVICE FOR A WINCH

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels

# data[].attributes.body.value
This CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis).

For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulate matter present in mining environments are points of regulatory concern. For some time, collecting airborne dust samples and subsequent determination of quartz content have been integral for assessing mine worker exposure and demonstrating compliance with US Federal regulations.

Unfortunately, highly accurate spectrometric detection and quantification of particulate exposure has not always been possible. Generally, the filters used in existing oscillating microbalances (such as the TEOM® monitor) have been specially designed to for hydrophobicity, in order to retain as little moisture as possible on the filter. These specialized hydrophobic filters (and/or their mounting components) contain inorganic compounds that cannot be readily subjected to thermal or chemical destruction - a necessary first step of many instrumental analytical methods, such as spectroscopy.

This CDC-developed filter consists of entirely ashable material, making it ideal for spectrometric analysis and rapid exposure assessment. As an example, this dust monitor filter can be made entirely of organic materials and designed for quick, easy ashing that will not produce interference with the spectroscopic characteristics of the chosen analyte(s). Further, filter ashing can be carried out by a variety of methods: thermal ashing, microwave ashing, low temperature ashing, or chemical destruction.

# data[].attributes.body.processed
This CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis).

For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulate matter present in mining environments are points of regulatory concern. For some time, collecting airborne dust samples and subsequent determination of quartz content have been integral for assessing mine worker exposure and demonstrating compliance with US Federal regulations.

Unfortunately, highly accurate spectrometric detection and quantification of particulate exposure has not always been possible. Generally, the filters used in existing oscillating microbalances (such as the TEOM® monitor) have been specially designed to for hydrophobicity, in order to retain as little moisture as possible on the filter. These specialized hydrophobic filters (and/or their mounting components) contain inorganic compounds that cannot be readily subjected to thermal or chemical destruction - a necessary first step of many instrumental analytical methods, such as spectroscopy.

This CDC-developed filter consists of entirely ashable material, making it ideal for spectrometric analysis and rapid exposure assessment. As an example, this dust monitor filter can be made entirely of organic materials and designed for quick, easy ashing that will not produce interference with the spectroscopic characteristics of the chosen analyte(s). Further, filter ashing can be carried out by a variety of methods: thermal ashing, microwave ashing, low temperature ashing, or chemical destruction.

# data[].attributes.field_commercial_applications.value
Personal dust monitors worn wherever dust exposure levels and the presence of potentially injurious materials is evaluated

Occupationally-mandated pneumoconiosis, asbestosis and/or silicosis prevention and monitoring programs, for complying with safety regulations

Miners' wellness concern groups and insurance companies

# data[].attributes.field_commercial_applications.processed
Personal dust monitors worn wherever dust exposure levels and the presence of potentially injurious materials is evaluated

Occupationally-mandated pneumoconiosis, asbestosis and/or silicosis prevention and monitoring programs, for complying with safety regulations

Miners' wellness concern groups and insurance companies

# data[].attributes.field_competitive_advantages.value
Novel dust-monitoring instrument capable of providing near rapid particulate exposure information to miners/users

Improves upon older technology by allowing for accurate detection and quantification of chosen analyte(s) and, unlike other filters, does not produce overlap or interfere with spectroscopic analysis

Filter can be easily ashed for analysis by thermal ashing, microwave ashing, low temperature ashing, or chemical destruction

# data[].attributes.field_competitive_advantages.processed
Novel dust-monitoring instrument capable of providing near rapid particulate exposure information to miners/users

Improves upon older technology by allowing for accurate detection and quantification of chosen analyte(s) and, unlike other filters, does not produce overlap or interfere with spectroscopic analysis

Filter can be easily ashed for analysis by thermal ashing, microwave ashing, low temperature ashing, or chemical destruction

# data[].attributes.field_development_status.value
Early-stage

In vitro data available

# data[].attributes.field_development_status.processed
Early-stage

In vitro data available

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2006/023166
Filed on 2006-06-14
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2006/023166
Filed on 2006-06-14
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/691,564
Filed on 2005-06-17
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/691,564
Filed on 2005-06-17
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,947,503
Filed on 2007-12-14
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,947,503
Filed on 2007-12-14
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2006/023166
Filed on 2006-06-14
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/691,564
Filed on 2005-06-17
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,947,503
Filed on 2007-12-14
Status: Abandoned

# data[].attributes.field_patent_titles[]
MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES

# data[].attributes.field_patent_titles[]
MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES

# data[].attributes.field_patent_titles[]
MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES

# data[].attributes.field_publications[].value
Tuchman DP.

# data[].attributes.field_publications[].processed
Tuchman DP.

# data[].attributes.field_technology_names[]
MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities

# data[].attributes.body.value
This invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, in situ testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m³ or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized particles during the manufacture, handling, and cleanup of engineered nanomaterials. Compared to other technologies, this CDC aerosol generator is particularly helpful when used for generating high testing concentrations of MWCNT aerosols that more accurately represent particulate levels that may be seen in a workplace environment.

# data[].attributes.body.processed
This invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, in situ testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m³ or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized particles during the manufacture, handling, and cleanup of engineered nanomaterials. Compared to other technologies, this CDC aerosol generator is particularly helpful when used for generating high testing concentrations of MWCNT aerosols that more accurately represent particulate levels that may be seen in a workplace environment.

# data[].attributes.field_commercial_applications.value
Studying the size and shape of the aerosolized particles produced from simple vibrations of bulk material

Toxicological investigations and risk assessment of aerosol exposures, especially those related to nanoparticle manufacturing

Any aerosolization application where the aggregating “bird's nest” tendencies of airborne multi-walled carbon nanotubes must be overcome

# data[].attributes.field_commercial_applications.processed
Studying the size and shape of the aerosolized particles produced from simple vibrations of bulk material

Toxicological investigations and risk assessment of aerosol exposures, especially those related to nanoparticle manufacturing

Any aerosolization application where the aggregating “bird's nest” tendencies of airborne multi-walled carbon nanotubes must be overcome

# data[].attributes.field_competitive_advantages.value
Fully automated system with integrated feedback control for optimized stability in testing

Maintains concentration of aerosols for >30 hours at concentrations of 15 mg/cubic meter or more

Capable of generating high concentrations of aerosols that more accurately represent the levels seen in a workplace environment

System insures that each run produces a constant particle concentration, air flow, pressure, temperature and humidity within a testing chamber

# data[].attributes.field_competitive_advantages.processed
Fully automated system with integrated feedback control for optimized stability in testing

Maintains concentration of aerosols for >30 hours at concentrations of 15 mg/cubic meter or more

Capable of generating high concentrations of aerosols that more accurately represent the levels seen in a workplace environment

System insures that each run produces a constant particle concentration, air flow, pressure, temperature and humidity within a testing chamber

# data[].attributes.field_development_status.value
In vitro data available

In vivo data available (animal)

In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In vitro data available

In vivo data available (animal)

In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/237,945
Filed on 2009-08-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/237,945
Filed on 2009-08-28
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,875,702
Filed on 2010-08-30
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,875,702
Filed on 2010-08-30
Status: Abandoned

# data[].attributes.field_patents[].value
US
Divisional (DIV) 14/473,324
Filed on 2014-08-29
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Divisional (DIV) 14/473,324
Filed on 2014-08-29
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/237,945
Filed on 2009-08-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,875,702
Filed on 2010-08-30
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Divisional (DIV) 14/473,324
Filed on 2014-08-29
Status: Abandoned

# data[].attributes.field_publications[].value
McKinney W, et al.

# data[].attributes.field_publications[].processed
McKinney W, et al.

# data[].attributes.field_publications[].value
Porter DW, et al.

# data[].attributes.field_publications[].processed
Porter DW, et al.

# data[].attributes.field_publications[].value
Porter DW, et al.

# data[].attributes.field_publications[].processed
Porter DW, et al.

# data[].attributes.field_publications[].value
Chen BT, et al.

# data[].attributes.field_publications[].processed
Chen BT, et al.

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment

# data[].attributes.body.value
CDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing.

In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of silica sand during each stage of fracturing. While a variety of passive and active controls are currently available (or have been proposed) to limit release of silica-containing dusts, the CDC/NIOSH mini-baghouse retrofit assembly was designed to fill a unique need for a control. The retrofit to equipment can be made in the field, uses existing energy inherent in the system and is relatively simple and effective. CDC/NIOSH field research has shown that risks for exposure to respirable silica arise from at least 8 points of dust generation and that a variety of controls (engineering, administrative and personal protective equipment) are needed to control exposures. Use of the mini-baghouse retrofit technology is intended to limit release of respirable silica from thief hatches on top of the sand movers, enhancing workplace health and safety.

# data[].attributes.body.processed
CDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing.

In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of silica sand during each stage of fracturing. While a variety of passive and active controls are currently available (or have been proposed) to limit release of silica-containing dusts, the CDC/NIOSH mini-baghouse retrofit assembly was designed to fill a unique need for a control. The retrofit to equipment can be made in the field, uses existing energy inherent in the system and is relatively simple and effective. CDC/NIOSH field research has shown that risks for exposure to respirable silica arise from at least 8 points of dust generation and that a variety of controls (engineering, administrative and personal protective equipment) are needed to control exposures. Use of the mini-baghouse retrofit technology is intended to limit release of respirable silica from thief hatches on top of the sand movers, enhancing workplace health and safety.

# data[].attributes.field_commercial_applications.value
Controlling occupational exposure to respirable crystalline silica, particularly during work involving transfer of sand into sand movers on hydraulic fracturing sites

In-field retrofits of currently operating heavy equipment (e.g., sand movers)

Limiting visible dust emissions from sand moving equipment

Reducing respirable crystalline silica dust emissions to enhance compliance with OSHA PEL for silica

# data[].attributes.field_commercial_applications.processed
Controlling occupational exposure to respirable crystalline silica, particularly during work involving transfer of sand into sand movers on hydraulic fracturing sites

In-field retrofits of currently operating heavy equipment (e.g., sand movers)

Limiting visible dust emissions from sand moving equipment

Reducing respirable crystalline silica dust emissions to enhance compliance with OSHA PEL for silica

# data[].attributes.field_competitive_advantages.value
Designed for in-field retrofitting “thief hatches” of existing machinery

Uses energy inherent in the pneumatic transfer of sand

Provides a passive sand-mover-mounted control for silica release at hydraulic fracturing operations

# data[].attributes.field_competitive_advantages.processed
Designed for in-field retrofitting “thief hatches” of existing machinery

Uses energy inherent in the pneumatic transfer of sand

Provides a passive sand-mover-mounted control for silica release at hydraulic fracturing operations

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment.

# data[].attributes.field_patents[].value
US Patent 9,669,345
Filed on 2016-01-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 9,669,345
Filed on 2016-01-11
Status: Abandoned

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/673,658
Filed on 2012-07-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/673,658
Filed on 2012-07-19
Status: Abandoned

# data[].attributes.field_patents[].value
US
Ordinary Patent (ORD) 13/802,265
Filed on 2013-03-13
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Ordinary Patent (ORD) 13/802,265
Filed on 2013-03-13
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 9,669,345
Filed on 2016-01-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/673,658
Filed on 2012-07-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Ordinary Patent (ORD) 13/802,265
Filed on 2013-03-13
Status: Abandoned

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR CONTROLLING PARTICULATE RELEASE FROM LARGE EQUIPMENT

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT

# data[].attributes.field_publications[].value
Esswein EJ, et al.

# data[].attributes.field_publications[].processed
Esswein EJ, et al.

# data[].attributes.field_technology_names[]
Multiple Mini Baghouse Retrofit For Control Of Respirable Crystalline Silica Release From Hydraulic Fracturing Sand Movers

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis

# data[].attributes.body.value
Micro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression.

# data[].attributes.body.processed
Micro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression.

# data[].attributes.field_commercial_applications.value
Medical/cytology training, education and certification

All aspects of applied microscopy/histology, microbial smears, hematology, parasitology, etc.

Clinical diagnostics

Basic and applied biology lab research

Forensic analysis

# data[].attributes.field_commercial_applications.processed
Medical/cytology training, education and certification

All aspects of applied microscopy/histology, microbial smears, hematology, parasitology, etc.

Clinical diagnostics

Basic and applied biology lab research

Forensic analysis

# data[].attributes.field_competitive_advantages.value
Readily adaptable to other microscopic disciplines

Automated imaging and display provides increased cost efficiency and improves objectivity of analysis and testing

Can be used to develop a database of standards or reference images for a variety of pathologies and/or applied microscopy concerns

# data[].attributes.field_competitive_advantages.processed
Readily adaptable to other microscopic disciplines

Automated imaging and display provides increased cost efficiency and improves objectivity of analysis and testing

Can be used to develop a database of standards or reference images for a variety of pathologies and/or applied microscopy concerns

# data[].attributes.field_development_status.value
In vitro data available

In situ data available (on-site)

# data[].attributes.field_development_status.processed
In vitro data available

In situ data available (on-site)

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/248,948
Filed on 2000-11-14
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/248,948
Filed on 2000-11-14
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,027,628
Filed on 2001-11-13
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,027,628
Filed on 2001-11-13
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,305,109
Filed on 2006-02-01
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,305,109
Filed on 2006-02-01
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/248,948
Filed on 2000-11-14
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,027,628
Filed on 2001-11-13
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,305,109
Filed on 2006-02-01
Status: Expired

# data[].attributes.field_patent_titles[]
Automated Microscopic Image Acquisition, Compositing, And Display

# data[].attributes.field_patent_titles[]
Automated Microscopic Image Acquisition, Compositing, And Display

# data[].attributes.field_patent_titles[]
Automated Microscopic Image Acquisition, Compositing, And Display

# data[].attributes.field_publications[].value
Taylor RN, et al.

# data[].attributes.field_publications[].processed
Taylor RN, et al.

# data[].attributes.field_technology_names[]
Automated Microscopic Image Acquisition, Compositing, And Display

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform

# data[].attributes.body.value
This CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer.

Current methods require expensive instantaneous and short-term monitors or gravimetric filters that must be carefully pre- and post-weighed to determine the average dust exposure of a user's work-shift. This novel dust dosimeter fills the need for an inexpensive short-term determination of personal dust exposure aiding in the assessment and preservation of worker respiratory health.

# data[].attributes.body.processed
This CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer.

Current methods require expensive instantaneous and short-term monitors or gravimetric filters that must be carefully pre- and post-weighed to determine the average dust exposure of a user's work-shift. This novel dust dosimeter fills the need for an inexpensive short-term determination of personal dust exposure aiding in the assessment and preservation of worker respiratory health.

# data[].attributes.field_commercial_applications.value
Dust, gas and particulate detector/dosimeter manufacturers

Industry applications where worker-exposure to dust will be a concern, especially mining, construction and demolition fields

Worker health and safety, related insurance agency concerns

# data[].attributes.field_commercial_applications.processed
Dust, gas and particulate detector/dosimeter manufacturers

Industry applications where worker-exposure to dust will be a concern, especially mining, construction and demolition fields

Worker health and safety, related insurance agency concerns

# data[].attributes.field_competitive_advantages.value
Provides inexpensive, short-term assessment of personal dust exposure

Gas detector tube platform makes commercialization of this instrument quite simple and efficient for related manufacturers/distributors

Standardizing detection platforms increases cost-efficiency (especially for smaller companies) as the same pump can be used to measure both dust and gas

# data[].attributes.field_competitive_advantages.processed
Provides inexpensive, short-term assessment of personal dust exposure

Gas detector tube platform makes commercialization of this instrument quite simple and efficient for related manufacturers/distributors

Standardizing detection platforms increases cost-efficiency (especially for smaller companies) as the same pump can be used to measure both dust and gas

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1998/013267
Filed on 1998-06-26
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1998/013267
Filed on 1998-06-26
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/052,719
Filed on 1997-07-03
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/052,719
Filed on 1997-07-03
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 6,401,520
Filed on 1999-12-21
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 6,401,520
Filed on 1999-12-21
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1998/013267
Filed on 1998-06-26
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/052,719
Filed on 1997-07-03
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 6,401,520
Filed on 1999-12-21
Status: Expired

# data[].attributes.field_publications[].value
Volkwein JC, et al.

# data[].attributes.field_publications[].processed
Volkwein JC, et al.

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds

# data[].attributes.body.value
This CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the listener to hear and interpret the subtleties of a recorded respiratory maneuver.

This device includes a software program that allows a user to select prerecorded sounds for playback. The program will also generate an inverse model of the playback system in the form of a digital filter. The inverse model processes a selected sound to cancel the distortions of the playback system so the sound is accurately reproduced. The program also permits the extraction of a specific sound component from a prerecorded sound so only the extracted sound component is audible during playback. In addition to the obvious role of a teaching tool for medical professionals, this invention could have applications as a diagnostic screening and/or telemedicine tool.

# data[].attributes.body.processed
This CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the listener to hear and interpret the subtleties of a recorded respiratory maneuver.

This device includes a software program that allows a user to select prerecorded sounds for playback. The program will also generate an inverse model of the playback system in the form of a digital filter. The inverse model processes a selected sound to cancel the distortions of the playback system so the sound is accurately reproduced. The program also permits the extraction of a specific sound component from a prerecorded sound so only the extracted sound component is audible during playback. In addition to the obvious role of a teaching tool for medical professionals, this invention could have applications as a diagnostic screening and/or telemedicine tool.

# data[].attributes.field_commercial_applications.value
Auscultatory training for health care professionals

Telemedicine tool

Diagnostic screening comparison and control

# data[].attributes.field_commercial_applications.processed
Auscultatory training for health care professionals

Telemedicine tool

Diagnostic screening comparison and control

# data[].attributes.field_competitive_advantages.value
Accurate, realistic reproduction of in situ physiological sounds

Apparatus features noise-cancelling filter to eliminate ambient distortion artifacts during playback

Device is extremely portable

Allows for isolation and playback of specific elements of a recording

# data[].attributes.field_competitive_advantages.processed
Accurate, realistic reproduction of in situ physiological sounds

Apparatus features noise-cancelling filter to eliminate ambient distortion artifacts during playback

Device is extremely portable

Allows for isolation and playback of specific elements of a recording

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/287,941
Filed on 2001-04-30
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/287,941
Filed on 2001-04-30
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,209,796
Filed on 2002-04-29
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,209,796
Filed on 2002-04-29
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/287,941
Filed on 2001-04-30
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,209,796
Filed on 2002-04-29
Status: Expired

# data[].attributes.field_publications[].value
Goldsmith WT, et al.

# data[].attributes.field_publications[].processed
Goldsmith WT, et al.

# data[].attributes.field_publications[].value
Abaza AA, et al.

# data[].attributes.field_publications[].processed
Abaza AA, et al.

# data[].attributes.field_related_inventions[].processed
E-245-2013-0

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures

# data[].attributes.body.value
This technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures.  The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules.  The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber.  For example, practical applications of this monitor/analysis technology would easily extend to use in mining operations (where both DPM and respirable dust exist in abundance), industrial manufacturing facilities, and anywhere that frequent or extended exposure to fuel-combustion exhaust or airborne pollution is a concern.  Further, by virtue of its ability to distinguish “fire smoke” from other aerosols that may be present, the device also has significant potential for use in early-warning fire detection.

# data[].attributes.body.processed
This technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures.  The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules.  The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber.  For example, practical applications of this monitor/analysis technology would easily extend to use in mining operations (where both DPM and respirable dust exist in abundance), industrial manufacturing facilities, and anywhere that frequent or extended exposure to fuel-combustion exhaust or airborne pollution is a concern.  Further, by virtue of its ability to distinguish “fire smoke” from other aerosols that may be present, the device also has significant potential for use in early-warning fire detection.

# data[].attributes.field_commercial_applications.value
Airborne particle monitor for mining and industrial manufacturing operations

Addressing emissions control standards and regulations

Early-warning fire detection in locations where traditional smoke-detector use is impractical

# data[].attributes.field_commercial_applications.processed
Airborne particle monitor for mining and industrial manufacturing operations

Addressing emissions control standards and regulations

Early-warning fire detection in locations where traditional smoke-detector use is impractical

# data[].attributes.field_competitive_advantages.value
Inexpensive and simple to implement

Device provides continuous, simultaneous, and independent measurement of both respirable dust and diesel particulate matter (DPM) mass concentrations

Previous particulate counting technologies are both expensive and cannot provide accurate quantification of coarse/fine aerosol mixtures, concentrations

# data[].attributes.field_competitive_advantages.processed
Inexpensive and simple to implement

Device provides continuous, simultaneous, and independent measurement of both respirable dust and diesel particulate matter (DPM) mass concentrations

Previous particulate counting technologies are both expensive and cannot provide accurate quantification of coarse/fine aerosol mixtures, concentrations

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/369,537
Filed on 2002-04-01
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/369,537
Filed on 2002-04-01
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 6,965,240
Filed on 2003-03-27
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 6,965,240
Filed on 2003-03-27
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/369,537
Filed on 2002-04-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 6,965,240
Filed on 2003-03-27
Status: Abandoned

# data[].attributes.field_patent_titles[]
Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors

# data[].attributes.field_patent_titles[]
Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors

# data[].attributes.field_technology_names[]
Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro

# data[].attributes.body.value
CDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway in vitro. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through electrogenic ion transport and releases factors that regulate the ability of smooth muscle to contract.

This invention allows for the measurement and study of pulmonary diseases under conditions retaining normal spatial relationships between all the cell types and an unmanipulated/undistorted tracheal airway wall. Further, the device permits evaluation of epithelial functional integrity using pharmacological techniques. Agents can be separately added to the lumen, where they must first cross the epithelium to reach the smooth muscle, or to the outside of the airway, where there is no hindrance of said agents to the muscle. The invention also permits the effective in vitro screening of the effects of agents and drugs on airway epithelium and smooth muscle within the same preparation.

# data[].attributes.body.processed
CDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway in vitro. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through electrogenic ion transport and releases factors that regulate the ability of smooth muscle to contract.

This invention allows for the measurement and study of pulmonary diseases under conditions retaining normal spatial relationships between all the cell types and an unmanipulated/undistorted tracheal airway wall. Further, the device permits evaluation of epithelial functional integrity using pharmacological techniques. Agents can be separately added to the lumen, where they must first cross the epithelium to reach the smooth muscle, or to the outside of the airway, where there is no hindrance of said agents to the muscle. The invention also permits the effective in vitro screening of the effects of agents and drugs on airway epithelium and smooth muscle within the same preparation.

# data[].attributes.field_commercial_applications.value
Investigations into physiological mechanisms of airway diseases, such as cystic fibrosis and asthma

Screening of drugs and therapeutic compounds directed to complex, multi-tissue type matrices

Biomedical research exploring pharmacology-physiology integration

# data[].attributes.field_commercial_applications.processed
Investigations into physiological mechanisms of airway diseases, such as cystic fibrosis and asthma

Screening of drugs and therapeutic compounds directed to complex, multi-tissue type matrices

Biomedical research exploring pharmacology-physiology integration

# data[].attributes.field_competitive_advantages.value
Allows simultaneous measurement of transepithelial potential difference, transepithelial resistance, smooth muscle activity and changes in tracheal diameter

In vitro analysis of trachea or tracheal segments retaining native, in situ structure

Pharmacological agents may be added separately to the lumen for screening purposes

First and only such "single-preparation" device allowing for such broad array of data output

# data[].attributes.field_competitive_advantages.processed
Allows simultaneous measurement of transepithelial potential difference, transepithelial resistance, smooth muscle activity and changes in tracheal diameter

In vitro analysis of trachea or tracheal segments retaining native, in situ structure

Pharmacological agents may be added separately to the lumen for screening purposes

First and only such "single-preparation" device allowing for such broad array of data output

# data[].attributes.field_development_status.value
Early-stage

In vitro data available

In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
Early-stage

In vitro data available

In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro.

# data[].attributes.field_patents[].value
US Patent 7,907,999
Filed on 2007-01-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,907,999
Filed on 2007-01-19
Status: Abandoned

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/762,465
Filed on 2006-01-25
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/762,465
Filed on 2006-01-25
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,907,999
Filed on 2007-01-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/762,465
Filed on 2006-01-25
Status: Abandoned

# data[].attributes.field_patent_titles[]
Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro

# data[].attributes.field_patent_titles[]
Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro

# data[].attributes.field_publications[].value
JIng Y, et. al.

# data[].attributes.field_publications[].processed
JIng Y, et. al.

# data[].attributes.field_technology_names[]
Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), East Carolina University

# data[].attributes.title
Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement

# data[].attributes.body.value
CDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength.  Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method.  In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle.  The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstrates that the measurement is independent of the loading position along the handle.  For real-world applications, the device can be used to help diagnose the musculoskeletal disorders of the hand, monitor the recovery progress after hand surgery or injury, and collect grip strength data for tool and machine design.

# data[].attributes.body.processed
CDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength.  Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method.  In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle.  The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstrates that the measurement is independent of the loading position along the handle.  For real-world applications, the device can be used to help diagnose the musculoskeletal disorders of the hand, monitor the recovery progress after hand surgery or injury, and collect grip strength data for tool and machine design.

# data[].attributes.field_commercial_applications.value
Useful for engineering functional design and ergonomic considerations for developing new tools and machinery

Monitoring post-operative, post-stroke rehabilitation

Diagnosis of carpel tunnel syndrome, musculoskeletal disorders and hand-arm vibration syndrome

Training feedback for grip-strength focused athletes - climbing, gymnastics, rugby, martial arts, etc.

# data[].attributes.field_commercial_applications.processed
Useful for engineering functional design and ergonomic considerations for developing new tools and machinery

Monitoring post-operative, post-stroke rehabilitation

Diagnosis of carpel tunnel syndrome, musculoskeletal disorders and hand-arm vibration syndrome

Training feedback for grip-strength focused athletes - climbing, gymnastics, rugby, martial arts, etc.

# data[].attributes.field_competitive_advantages.value
Compared to currently used "Jamar" grip test devices:

Cylindrical handle shape more comparable with real-world/workplace machinery

Improved comfort

Cylindrical meter assesses the total grip force, together with the friction force and torque

Grip force distributed at the different parts of the hand can be measured with cylindrical meter - important information for the diagnosis of hand disorders

# data[].attributes.field_competitive_advantages.processed
Compared to currently used "Jamar" grip test devices:

Cylindrical handle shape more comparable with real-world/workplace machinery

Improved comfort

Cylindrical meter assesses the total grip force, together with the friction force and torque

Grip force distributed at the different parts of the hand can be measured with cylindrical meter - important information for the diagnosis of hand disorders

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/175,473
Filed on 2009-05-05
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/175,473
Filed on 2009-05-05
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,240,202
Filed on 2010-05-04
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,240,202
Filed on 2010-05-04
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/175,473
Filed on 2009-05-05
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,240,202
Filed on 2010-05-04
Status: Abandoned

# data[].attributes.field_patent_titles[]
HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT

# data[].attributes.field_patent_titles[]
HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT

# data[].attributes.field_publications[].value
Wimer B, et al.

# data[].attributes.field_publications[].processed
Wimer B, et al.

# data[].attributes.field_technology_names[]
HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency

# data[].attributes.body.value
Improper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination.

CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthropometric method, and that it was also significantly faster than the bubble indicator method. When properly implemented, this effective and easy to use ladder positioning indicator will reduce the risk of extension ladder slipping and tipping and, ultimately, will reduce the number of fall incidents and injuries – benefitting construction workers, employers, contractors and workplace insurers.

# data[].attributes.body.processed
Improper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination.

CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthropometric method, and that it was also significantly faster than the bubble indicator method. When properly implemented, this effective and easy to use ladder positioning indicator will reduce the risk of extension ladder slipping and tipping and, ultimately, will reduce the number of fall incidents and injuries – benefitting construction workers, employers, contractors and workplace insurers.

# data[].attributes.field_commercial_applications.value
Retrofitting existing ladders to provide automated, multisensory feedback for improved compliance with OSHA and ANSI ladder-angle safety guidelines

Ladder manufacturing companies

Construction contractors, retailers and insurers

Training tool to aid worker safety education and adherence

# data[].attributes.field_commercial_applications.processed
Retrofitting existing ladders to provide automated, multisensory feedback for improved compliance with OSHA and ANSI ladder-angle safety guidelines

Ladder manufacturing companies

Construction contractors, retailers and insurers

Training tool to aid worker safety education and adherence

# data[].attributes.field_competitive_advantages.value
Direct, multimodal user feedback reduces the time for accurate, safe ladder positioning compared to bubble-level indicator, anthropometric and sight- based ladder-positioning methods

Visual, auditory and tactile feedback provide increased efficient-setup and safety

Technology can be incorporated as an attachable, device which may be affixed to a ladder or integrated as an app for a mobile/tablet device

Automated feedback ensures ladders are angled to OSHA and ANSI safety specifications

# data[].attributes.field_competitive_advantages.processed
Direct, multimodal user feedback reduces the time for accurate, safe ladder positioning compared to bubble-level indicator, anthropometric and sight- based ladder-positioning methods

Visual, auditory and tactile feedback provide increased efficient-setup and safety

Technology can be incorporated as an attachable, device which may be affixed to a ladder or integrated as an app for a mobile/tablet device

Automated feedback ensures ladders are angled to OSHA and ANSI safety specifications

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency.

# data[].attributes.field_patents[].value
US Patent 8,167,087
Filed on 2009-03-09
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,167,087
Filed on 2009-03-09
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 8,167,087
Filed on 2009-03-09
Status: Issued

# data[].attributes.field_patent_titles[]
Multimodal Indicator Safety Device For Ladder Positioning

# data[].attributes.field_publications[].value
Simeonov P, et al.

# data[].attributes.field_publications[].processed
Simeonov P, et al.

# data[].attributes.field_technology_names[]
Multimodal Indicator Safety Device For Ladder Positioning

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate

# data[].attributes.body.value
This CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective sampling errors at low flow rates.

Performance of this PSP is not degraded by pump inertia or low flow size selective sampling errors. This design maintains a consistent pump speed, controlling PSP sampling rate with calibrated valves that redirect air flow almost instantaneously. In situ device testing demonstrated that when this air-flow valve is properly integrated into a sampling head, response time of the PSP is essentially mutually exclusive of the magnitude of changes in the effective flow, facilitating consistently small error in sampling performance regardless of user-exertion scenario.

# data[].attributes.body.processed
This CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective sampling errors at low flow rates.

Performance of this PSP is not degraded by pump inertia or low flow size selective sampling errors. This design maintains a consistent pump speed, controlling PSP sampling rate with calibrated valves that redirect air flow almost instantaneously. In situ device testing demonstrated that when this air-flow valve is properly integrated into a sampling head, response time of the PSP is essentially mutually exclusive of the magnitude of changes in the effective flow, facilitating consistently small error in sampling performance regardless of user-exertion scenario.

# data[].attributes.field_commercial_applications.value
Air sampling device manufacturers

Assessing airborne hazard exposures for workplace safety

Industrial hygiene programs

Respiration monitoring device for patients

Aerobic training system for athletes

# data[].attributes.field_commercial_applications.processed
Air sampling device manufacturers

Assessing airborne hazard exposures for workplace safety

Industrial hygiene programs

Respiration monitoring device for patients

Aerobic training system for athletes

# data[].attributes.field_competitive_advantages.value
Allows for air sampling to be modulated to follow breathing rate

Design obviates the sluggishness inherent in prior art physiologic sampling pumps (PSPs) caused by variable pump speed effect on sampling rate

Improved accuracy compared to earlier PSPs, irrelevant of user-exertion scenarios

Follows inhalation on a breath-by-breath basis

# data[].attributes.field_competitive_advantages.processed
Allows for air sampling to be modulated to follow breathing rate

Design obviates the sluggishness inherent in prior art physiologic sampling pumps (PSPs) caused by variable pump speed effect on sampling rate

Improved accuracy compared to earlier PSPs, irrelevant of user-exertion scenarios

Follows inhalation on a breath-by-breath basis

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/145,777
Filed on 2010-01-20
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/145,777
Filed on 2010-01-20
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,459,098
Filed on 2010-01-20
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,459,098
Filed on 2010-01-20
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/145,777
Filed on 2010-01-20
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,459,098
Filed on 2010-01-20
Status: Issued

# data[].attributes.field_patent_titles[]
Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing

# data[].attributes.field_patent_titles[]
Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing

# data[].attributes.field_publications[].value
Lee L, et al.

# data[].attributes.field_publications[].processed
Lee L, et al.

# data[].attributes.field_technology_names[]
A Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities

# data[].attributes.body.value
This CDC invention entails methods and apparatuses for in situ testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator and/or application.

By correlating user activity to seal sensor data, a precise understanding and awareness of respirator integrity may be obtained. When coupled with a subject alarm, these integrated values can immediately alert a user when a threshold of environmental exposure has been reached. Such real-time feedback will be invaluable to users in dangerous occupational activities, such as firefighters, biodefense and chemical spill first responders, mining applications, etc. Additionally, this invention possesses immense value for respirator mask manufacturers and workplace training programs for employees engaged in mandatory respirator usage applications.

# data[].attributes.body.processed
This CDC invention entails methods and apparatuses for in situ testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator and/or application.

By correlating user activity to seal sensor data, a precise understanding and awareness of respirator integrity may be obtained. When coupled with a subject alarm, these integrated values can immediately alert a user when a threshold of environmental exposure has been reached. Such real-time feedback will be invaluable to users in dangerous occupational activities, such as firefighters, biodefense and chemical spill first responders, mining applications, etc. Additionally, this invention possesses immense value for respirator mask manufacturers and workplace training programs for employees engaged in mandatory respirator usage applications.

# data[].attributes.field_commercial_applications.value
Manufacturers of respirators, leakage assessment devices and applied ultrasonic technology

Regulators of respiratory protection plans

Biohazard, biodefense and hazardous chemical handling and disposal

Surgery/hospital training and use

# data[].attributes.field_commercial_applications.processed
Manufacturers of respirators, leakage assessment devices and applied ultrasonic technology

Regulators of respiratory protection plans

Biohazard, biodefense and hazardous chemical handling and disposal

Surgery/hospital training and use

# data[].attributes.field_competitive_advantages.value
Small, low power consuming, and inexpensive apparatuses and methods may be employed

Real-time monitoring and feedback greatly diminish risk of user exposure to environmental hazards

# data[].attributes.field_competitive_advantages.processed
Small, low power consuming, and inexpensive apparatuses and methods may be employed

Real-time monitoring and feedback greatly diminish risk of user exposure to environmental hazards

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/329,846
Filed on 2012-04-30
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/329,846
Filed on 2012-04-30
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,573,199
Filed on 2011-05-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,573,199
Filed on 2011-05-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/329,846
Filed on 2012-04-30
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,573,199
Filed on 2011-05-02
Status: Abandoned

# data[].attributes.field_patent_titles[]
Ultrasonic In Situ Respiratory Mask Testing Process And Mask

# data[].attributes.field_patent_titles[]
Ultrasonic In Situ Respiratory Mask Testing Process And Mask

# data[].attributes.field_technology_names[]
Ultrasonic In Situ Respiratory Mask Testing Process And Mask

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples

# data[].attributes.body.value
This invention relates to detecting Histoplasma capsulatum by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by H. capsulatum, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.

Test samples may originate from the environment (soil, for example), where H. capsulatum spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay.

# data[].attributes.body.processed
This invention relates to detecting Histoplasma capsulatum by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by H. capsulatum, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.

Test samples may originate from the environment (soil, for example), where H. capsulatum spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay.

# data[].attributes.field_commercial_applications.value
Directing antifungal drug therapy for improved patient outcomes

Occupational health and safety screening for workers who may encounter bird or bat waste

Screening biological or soil samples for the presence of fungal pathogens

Environment testing for immunocompromised patients

# data[].attributes.field_commercial_applications.processed
Directing antifungal drug therapy for improved patient outcomes

Occupational health and safety screening for workers who may encounter bird or bat waste

Screening biological or soil samples for the presence of fungal pathogens

Environment testing for immunocompromised patients

# data[].attributes.field_competitive_advantages.value
Rapid and precise

Cost-effective

Easily adapted for H. capsulatum detection kits

Can positively identify small sample sizes of as few as 10 spores

High-throughput capable

# data[].attributes.field_competitive_advantages.processed
Rapid and precise

Cost-effective

Easily adapted for H. capsulatum detection kits

Can positively identify small sample sizes of as few as 10 spores

High-throughput capable

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/082,477
Filed on 1998-04-21
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/082,477
Filed on 1998-04-21
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1999/008731
Filed on 1999-04-20
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1999/008731
Filed on 1999-04-20
Status: Expired

# data[].attributes.field_patents[].value
US Patent 6,469,156
Filed on 2001-01-12
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 6,469,156
Filed on 2001-01-12
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/082,477
Filed on 1998-04-21
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1999/008731
Filed on 1999-04-20
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 6,469,156
Filed on 2001-01-12
Status: Expired

# data[].attributes.field_patent_titles[]
RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM

# data[].attributes.field_patent_titles[]
RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM

# data[].attributes.field_patent_titles[]
RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM

# data[].attributes.field_publications[].value
Reid TM, Schafer MP.

# data[].attributes.field_publications[].processed
Reid TM, Schafer MP.

# data[].attributes.field_publications[].value
CDC Fact Sheet: Histoplasmosis

# data[].attributes.field_publications[].processed
CDC Fact Sheet: Histoplasmosis

# data[].attributes.field_related_inventions[].processed
E-293-2013-0

# data[].attributes.field_related_inventions[].processed
E-332-2013-0

# data[].attributes.field_related_inventions[].processed
E-232-2013-0

# data[].attributes.field_related_inventions[].processed
E-335-2013-0

# data[].attributes.field_technology_names[]
RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production  Exposure-related Asthma and Allergy and Clinical Diagnosis

# data[].attributes.body.value
CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge.

This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination.

# data[].attributes.body.processed
CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge.

This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination.

# data[].attributes.field_commercial_applications.value
Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).

Clinical diagnostic use.

dNCO-induced allergy/asthma prevention by passive immunization

# data[].attributes.field_commercial_applications.processed
Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).

Clinical diagnostic use.

dNCO-induced allergy/asthma prevention by passive immunization

# data[].attributes.field_competitive_advantages.value
Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.

Two sandwich ELISAs have been developed and validated using human samples.

Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.

# data[].attributes.field_competitive_advantages.processed
Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.

Two sandwich ELISAs have been developed and validated using human samples.

Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.

# data[].attributes.field_development_status.value
Early-stage

In vitro data available

# data[].attributes.field_development_status.processed
Early-stage
In vitro data available

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production  Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production  Exposure-related Asthma and Allergy and Clinical Diagnosis.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production  Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production  Exposure-related Asthma and Allergy and Clinical Diagnosis.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/104,429
Filed on 2008-10-10
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/104,429
Filed on 2008-10-10
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,828,667
Filed on 2009-10-12
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,828,667
Filed on 2009-10-12
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/104,429
Filed on 2008-10-10
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,828,667
Filed on 2009-10-12
Status: Issued

# data[].attributes.field_patent_titles[]
Methods And Compositions Relating To Isocyanate Conjugates

# data[].attributes.field_patent_titles[]
Methods And Compositions Relating To Isocyanate Conjugates

# data[].attributes.field_publications[].value
Lemons AR, et al.

# data[].attributes.field_publications[].processed
Lemons AR, et al.

# data[].attributes.field_publications[].value
Ruwona TB, et al.

# data[].attributes.field_publications[].processed
Ruwona TB, et al.

# data[].attributes.field_publications[].value
Ruwona TB, et al.

# data[].attributes.field_publications[].processed
Ruwona TB, et al.

# data[].attributes.field_technology_names[]
Methods And Compositions Relating To Isocyanate Conjugates

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Warning System for Mobile Machinery Hazardous Zones

# data[].attributes.body.value
This invention relates to a warning system designed to protect individuals working near hazardous machinery.  The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal.  This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry.

# data[].attributes.body.processed
This invention relates to a warning system designed to protect individuals working near hazardous machinery.  The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal.  This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry.

# data[].attributes.field_commercial_applications.value
Auxiliary safety equipment for heavy machinery

Occupational health and safety

Mining worker safety

# data[].attributes.field_commercial_applications.processed
Auxiliary safety equipment for heavy machinery

Occupational health and safety

Mining worker safety

# data[].attributes.field_competitive_advantages.value
Easy transmitter installation

Signal can be adjusted for an audio or visual "warning zone alert" and a proximal "imminent danger zone alert"

# data[].attributes.field_competitive_advantages.processed
Easy transmitter installation

Signal can be adjusted for an audio or visual "warning zone alert" and a proximal "imminent danger zone alert"

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones.

# data[].attributes.field_patents[].value
US Patent 5,939,986
Filed on 1996-10-18
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 5,939,986
Filed on 1996-10-18
Status: Expired

# data[].attributes.field_patents[].value
US
Divisional (DIV) 09/575,475
Filed on 2000-05-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Divisional (DIV) 09/575,475
Filed on 2000-05-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 5,939,986
Filed on 1996-10-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Divisional (DIV) 09/575,475
Filed on 2000-05-19
Status: Abandoned

# data[].attributes.field_patent_titles[]
MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING SYSTEM

# data[].attributes.field_patent_titles[]
MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING

# data[].attributes.field_publications[].value
Schiffbauer WH.

# data[].attributes.field_publications[].processed
Schiffbauer WH.

# data[].attributes.field_technology_names[]
MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size

# data[].attributes.body.value
This invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere.  The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles.  Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size.  Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed.  Analysis may include, but is not limited to, PCR, immunoassay analysis, microscopic spore counting, and counting colony-forming units.  The device should also have many additional uses for environmental surveillance and occupational health applications.

# data[].attributes.body.processed
This invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere.  The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles.  Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size.  Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed.  Analysis may include, but is not limited to, PCR, immunoassay analysis, microscopic spore counting, and counting colony-forming units.  The device should also have many additional uses for environmental surveillance and occupational health applications.

# data[].attributes.field_commercial_applications.value
Analysis of ambient air particulates

Environmental surveillance

Occupational safety monitoring

Biodefense

Long-term exposure assessment

# data[].attributes.field_commercial_applications.processed
Analysis of ambient air particulates

Environmental surveillance

Occupational safety monitoring

Biodefense

Long-term exposure assessment

# data[].attributes.field_competitive_advantages.value
Rapid, on-site sampling and analysis.

Alternative to surface-sampling and culturing for aerosolized biological agents.

Superior extraction efficiency compared to filters, impingers, and impactors.

Real-world testing demonstrated device's ability to collect airborne mold and mycotoxins, pollen and pollen fragments, airborne dust particulates, as well as airborne influenza virus in a hospital environment.

# data[].attributes.field_competitive_advantages.processed
Rapid, on-site sampling and analysis.

Alternative to surface-sampling and culturing for aerosolized biological agents.

Superior extraction efficiency compared to filters, impingers, and impactors.

Real-world testing demonstrated device's ability to collect airborne mold and mycotoxins, pollen and pollen fragments, airborne dust particulates, as well as airborne influenza virus in a hospital environment.

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2004/032378
Filed on 2004-10-01
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2004/032378
Filed on 2004-10-01
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/512,252
Filed on 2003-10-17
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/512,252
Filed on 2003-10-17
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,370,543
Filed on 2006-04-04
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,370,543
Filed on 2006-04-04
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,205,511
Filed on 2008-05-12
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,205,511
Filed on 2008-05-12
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2004/032378
Filed on 2004-10-01
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/512,252
Filed on 2003-10-17
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,370,543
Filed on 2006-04-04
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,205,511
Filed on 2008-05-12
Status: Abandoned

# data[].attributes.field_publications[].value
Chen BT, et al.

# data[].attributes.field_publications[].processed
Chen BT, et al.

# data[].attributes.field_publications[].value
Macher JM, et al.

# data[].attributes.field_publications[].processed
Macher JM, et al.

# data[].attributes.field_publications[].value
Macher JM, et al.

# data[].attributes.field_publications[].processed
Macher JM, et al.

# data[].attributes.field_publications[].value
Su WC, et al.

# data[].attributes.field_publications[].processed
Su WC, et al.

# data[].attributes.field_publications[].value
Wang CH, et al.

# data[].attributes.field_publications[].processed
Wang CH, et al.

# data[].attributes.field_publications[].value
Lindsley WG, et al.

# data[].attributes.field_publications[].processed
Lindsley WG, et al.

# data[].attributes.field_publications[].value
Blachere FM, et al.

# data[].attributes.field_publications[].processed
Blachere FM, et al.

# data[].attributes.field_publications[].value
Lindsley WG, et al.

# data[].attributes.field_publications[].processed
Lindsley WG, et al.

# data[].attributes.field_publications[].value
Cao G, et al.

# data[].attributes.field_publications[].processed
Cao G, et al.

# data[].attributes.field_publications[].value
CDC-NIOSH Cyclone Bioaerosol Sampler webpage

# data[].attributes.field_publications[].processed
CDC-NIOSH Cyclone Bioaerosol Sampler webpage

# data[].attributes.field_publications[].value
NIOSH Personal Bioaerosol Cyclone Sampler video

# data[].attributes.field_publications[].processed
NIOSH Personal Bioaerosol Cyclone Sampler video

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation

# data[].attributes.body.value
This CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive chargers also tend to be too bulky for use in compact aerosolization instruments.
This invention circumvents these two critical drawbacks by eliminating radioactivity and miniaturizing overall unit size (1x0.75 x 0.5 inch). Other unique aspects of the invention entail elimination of the need for additional air flows (other than the aerosol sample flow), minimal power consumption, a low per-unit cost, and simplicity of operation. In all, excellent transmission efficiency, steady-state charging characteristics and the miniature size make this bipolar particle charger well-suited for integration with portable or personal aerosol instrumentation.

# data[].attributes.body.processed
This CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive chargers also tend to be too bulky for use in compact aerosolization instruments.
This invention circumvents these two critical drawbacks by eliminating radioactivity and miniaturizing overall unit size (1x0.75 x 0.5 inch). Other unique aspects of the invention entail elimination of the need for additional air flows (other than the aerosol sample flow), minimal power consumption, a low per-unit cost, and simplicity of operation. In all, excellent transmission efficiency, steady-state charging characteristics and the miniature size make this bipolar particle charger well-suited for integration with portable or personal aerosol instrumentation.

# data[].attributes.field_commercial_applications.value
Personal and portable aerosol instrumentation

Component of field-use device for determining workplace/environmental exposure to ultrafine aerosols and airborne nanoparticles

Tool for environmental/occupational health, toxicology, workplace control evaluations and hazard identification involving aerosol exposure

# data[].attributes.field_commercial_applications.processed
Personal and portable aerosol instrumentation

Component of field-use device for determining workplace/environmental exposure to ultrafine aerosols and airborne nanoparticles

Tool for environmental/occupational health, toxicology, workplace control evaluations and hazard identification involving aerosol exposure

# data[].attributes.field_competitive_advantages.value
Non-radioactive; no associated regulatory or transportation issues

Low-cost and requires very little power to operate

Additional air flows other than sample airflow are unnecessary

Unit is small (1x0.75x0.5in;2.54x1.91x1.27cm) and highly portable

Eliminates a major barrier for reliable aerosol sampling using "bipolar charger + differential mobility analyzer + condensation particle detector" scheme in a compact device

# data[].attributes.field_competitive_advantages.processed
Non-radioactive; no associated regulatory or transportation issues

Low-cost and requires very little power to operate

Additional air flows other than sample airflow are unnecessary

Unit is small (1x0.75x0.5in;2.54x1.91x1.27cm) and highly portable

Eliminates a major barrier for reliable aerosol sampling using "bipolar charger + differential mobility analyzer + condensation particle detector" scheme in a compact device

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation.

# data[].attributes.field_patents[].value
US Patent 8,611,066
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,611,066
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 8,611,066
Filed on 2011-12-09
Status: Issued

# data[].attributes.field_patent_titles[]
Non-Radioactive Bipolar Charger For Aerosol Particles

# data[].attributes.field_technology_names[]
Non-Radioactive Bipolar Charger For Aerosol Particles

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)

# data[].attributes.body.value
CDC NIOSH researchers have developed a simple and rapid detection technique for Stachybotrys chartarum (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in Stachybotrys chartarum. These antibodies can be used in immunologic detection assays to detect and possibly quantify Stachybotrys chartarum in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people) or allergies. Individuals with asthma or those with weaker immune systems can be affected more by mold exposure. Accurate detection methods are needed to measure mold contamination. Traditional methods for monitoring of molds are based on sample cultivation and microscopic analysis which can be time and labor intensive, and require expert classification skills. Immunoassays can potentially overcome these limitations and have been successfully developed for numerous biological aerosols. For more information on Stachybotrys chartarum and other molds, visit CDC’s fact page: www.cdc.gov/mold/stachy.htm.

# data[].attributes.body.processed
CDC NIOSH researchers have developed a simple and rapid detection technique for Stachybotrys chartarum (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in Stachybotrys chartarum. These antibodies can be used in immunologic detection assays to detect and possibly quantify Stachybotrys chartarum in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people) or allergies. Individuals with asthma or those with weaker immune systems can be affected more by mold exposure. Accurate detection methods are needed to measure mold contamination. Traditional methods for monitoring of molds are based on sample cultivation and microscopic analysis which can be time and labor intensive, and require expert classification skills. Immunoassays can potentially overcome these limitations and have been successfully developed for numerous biological aerosols. For more information on Stachybotrys chartarum and other molds, visit CDC’s fact page: www.cdc.gov/mold/stachy.htm.

# data[].attributes.field_commercial_applications.value
Detection of Stachybotrys chartarum antigens in contaminated building materials or field environments with a color-changing dipstick assay

Occupational health and home safety

# data[].attributes.field_commercial_applications.processed
Detection of Stachybotrys chartarum antigens in contaminated building materials or field environments with a color-changing dipstick assay

Occupational health and home safety

# data[].attributes.field_competitive_advantages.value
Simple, rapid, and specific detection of Stachybotrys chartarum

Easily adaptable for kit format

Less labor-intensive than spore counting or culturing

Adaptable for high sample volumes (or throughputs) being processed

Potential use in proteomics chip for screening multiple pathogens simultaneously

# data[].attributes.field_competitive_advantages.processed
Simple, rapid, and specific detection of Stachybotrys chartarum

Easily adaptable for kit format

Less labor-intensive than spore counting or culturing

Adaptable for high sample volumes (or throughputs) being processed

Potential use in proteomics chip for screening multiple pathogens simultaneously

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus).

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus).

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2002/025493
Filed on 2002-08-09
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2002/025493
Filed on 2002-08-09
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/311,458
Filed on 2001-08-10
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/311,458
Filed on 2001-08-10
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,368,256
Filed on 2004-01-14
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,368,256
Filed on 2004-01-14
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2002/025493
Filed on 2002-08-09
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/311,458
Filed on 2001-08-10
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,368,256
Filed on 2004-01-14
Status: Expired

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE

# data[].attributes.field_patent_titles[]
ANTIBODIES AGAINST STACHYBOTRYS CHARTARUM AND METHODS FOR THEIR USE

# data[].attributes.field_technology_names[]
MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Generation of Artificial Mutation Controls for Diagnostic Testing

# data[].attributes.body.value
This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of positive control material, as well as an alternative to patient-derived mutation-positive samples.

# data[].attributes.body.processed
This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of positive control material, as well as an alternative to patient-derived mutation-positive samples.

# data[].attributes.field_commercial_applications.value
Generation of positive controls for molecular genetic tests, particularly for tests to detect cystic fibrosis

# data[].attributes.field_commercial_applications.processed
Generation of positive controls for molecular genetic tests, particularly for tests to detect cystic fibrosis

# data[].attributes.field_competitive_advantages.value
Positive controls can be included in new kits or packaged with pre-existing assays

Increased accuracy in diagnosis compared to current controls

Consistent and renewable source for high-quality controls containing mutations of interest

# data[].attributes.field_competitive_advantages.processed
Positive controls can be included in new kits or packaged with pre-existing assays

Increased accuracy in diagnosis compared to current controls

Consistent and renewable source for high-quality controls containing mutations of interest

# data[].attributes.field_development_status.value
Early-stage

In vitro data available

# data[].attributes.field_development_status.processed
Early-stage

In vitro data available

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2005/008108
Filed on 2005-03-11
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2005/008108
Filed on 2005-03-11
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/552,979
Filed on 2004-03-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/552,979
Filed on 2004-03-11
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,603,745
Filed on 2006-09-05
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 8,603,745
Filed on 2006-09-05
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2005/008108
Filed on 2005-03-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/552,979
Filed on 2004-03-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,603,745
Filed on 2006-09-05
Status: Abandoned

# data[].attributes.field_patent_titles[]
Artificial Mutation Controls For Diagnostic Testing

# data[].attributes.field_patent_titles[]
Artificial Mutation Controls For Diagnostic Testing

# data[].attributes.field_patent_titles[]
Artificial Mutation Controls For Diagnostic Testing

# data[].attributes.field_technology_names[]
Artificial Mutation Controls For Diagnostic Testing

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), University of California, Los Angeles (UCLA)